Subscribe To
Continued strong cresemba® (isavuconazole) sales by astellas in the u.s. trigger chf 20 million sales milestone payment to basilea
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial a...
January 9, 2023, 6:29 am
Taysha gene therapies: astellas throws lifeline for first dibs on rett and gan programs
Shares have fallen by 85% since Sept 2020 IPO as cash resources dwindled to $34M as of last month. Company was forced to cut 35% of workforce, stop co...
November 17, 2022, 6:04 pm
astellas pharma, inc. (alpmf) management on q1 2022 results earnings call transcript
astellas Pharma, Inc. (OTCPK:ALPMF) Q1 2022 Earnings Conference Call August 1, 2022 3:00 AM ET Company ...
August 1, 2022, 11:23 am
Seagen shares positive data for bladder cancer drug; stock is up 2.5%
Shares of Seagen Inc. SGEN, +0.71% gained 2.5% in premarket trading on Tuesday after the company said an early-stage clinical trial evaluating its inv...
July 26, 2022, 7:30 am
astellas worth a look on revenue re-acceleration potential
astellas looks posed to exit a period of prolonged weak revenue growth and see acceleration into the mi...
March 9, 2022, 1:11 pm
astellas pharma - seagen's enfortumab shows 36% pathologic complete response in bladder cancer patients
Seagen Inc (NASDAQ: SGEN) and astellas Pharma Inc (OTC: ALPMF) announced the initial results from ...
February 15, 2022, 7:40 am
astellas pharma - seagen's enfortumab shows 36% pathologic complete response in bladder cancer patients
Seagen Inc (NASDAQ: SGEN) and astellas Pharma Inc (OTC: ALPMF) announced the initial results from ...
February 15, 2022, 7:40 am
astellas pharma - seagen's enfortumab shows 36% pathologic complete response in bladder cancer patients
Seagen Inc (NASDAQ: SGEN) and astellas Pharma Inc (OTC: ALPMF) announced the initial results from ...
February 15, 2022, 7:40 am